OliX PharmaceuticalsInc (226950 KQ) stock market data APIs
₩14500
420(3%)
as of January 20, 2025
OliX PharmaceuticalsInc Financial Data Overview
Price chart is built with
Anychart
OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Prev. Close
14080
Open
14500
Volume
142 K
High
14500
Low
13900
52 wk Range
8280-32750
Market Cap
243 921 M
Shares Outstanding
17 238 K
Revenue
17 899 M
EPS
-621.2854
Beta
0.699
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OliX PharmaceuticalsInc data using free add-ons & libraries
Get OliX PharmaceuticalsInc Fundamental Data
OliX PharmaceuticalsInc Fundamental data includes:
- Net Revenue: 17 899 M
- EBITDA: -14 004 162 560
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-11
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OliX PharmaceuticalsInc News
New
OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease
SUWON, South Korea, June 15, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. ha...
OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention
SUWON, South Korea, June 09, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will partic...
OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars
SUWON, South Korea, June 03, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the completion of patient enrollment in the...
OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvement
SUWON, South Korea, May 25, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has successfully completed a capi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
